Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
26 February 2018 Photo Eugene Seegers
Dutch scholar honours Faculty of Theology and Religion with special book dedication
Prof Bram van de Beek hands over his book, Mijn Vader, uw Vader, which contains his dedication to the UFS Faculty of Theology and Religion, to Prof Fanie Snyman, Dean of the faculty.

While surveying recent publications, staff members at the Faculty of Theology and Religion discovered, almost by coincidence, that a world-renowned systematic theologian and professor emeritus of the Free University Amsterdam (VU Amsterdam) in the Netherlands, Prof Bram van de Beek, had dedicated his most recent volume on Systematic Theology to the Faculty of Theology and Religion at the UFS in Bloemfontein.

Even before Prof Fanie Snyman, Dean of this faculty, had any knowledge of this special honour, Prof Van de Beek was invited to conduct the Scripture reading and sermon on the programme of the University of the Free State (UFS) Faculty of Theology and Religion’s official opening and Theological Day. This event provided the perfect opportunity for Prof Van de Beek to officially hand a copy of his book over to the faculty.

Prof Van de Beek accepted the invitation and on 19 February 2018 conducted the sermon in the Odeion Theatre at the UFS based on the theme of the Theological Day, Reconciliation: Biblical imperative and the South African reality. He then formally presented his book, with the title Mijn Vader, uw Vader, which contains the dedication, to Prof Snyman, saying: “It is an honour for me to have the opportunity to present my book today. It was a pleasure for me to dedicate it to the Faculty of Theology and Religion in Bloemfontein. I did so because of my great appreciation for the work these colleagues are doing.”

'It was a pleasure for me
to dedicate this book to the
UFS Faculty of Theology and Religion.'
—Prof Bram van de Beek
Dutch Systematical Theologian
and Dogmatician

Prof Van de Beek continued: “They keep to academic standards in difficult circumstances. It is not only the pressure of ‘publish or perish’ which must be resisted, but also the pressure of society, and most of all, of church members who want an adapted theology according to their desires. True theology, like any academic discipline, is interested in the truth and is not based on interests. I notice the courage by colleagues of this faculty to keep to this standard in both the training of students and in their research. They even had the courage to reflect on the very rationale of the existence of theology at a public university. Nothing can be taken for granted, for at the very moment we do so in the university, we lose our critical attitude, which is the basis for academic work. So it is with great esteem that I dedicated my book to this faculty.”

In his acceptance, Prof Snyman expressed his utmost appreciation that a European theologian of worldwide renown would take note of a university and faculty so far removed from his sphere of activity.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept